Edgestream Partners L.P. Has $3.09 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Edgestream Partners L.P. grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 228.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,286 shares of the company’s stock after purchasing an additional 32,202 shares during the quarter. Edgestream Partners L.P.’s holdings in Moderna were worth $3,093,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna during the 2nd quarter worth approximately $26,000. Family Firm Inc. bought a new position in shares of Moderna during the 2nd quarter worth approximately $33,000. Bank & Trust Co bought a new position in shares of Moderna during the 2nd quarter worth approximately $36,000. Hanseatic Management Services Inc. bought a new position in shares of Moderna during the 2nd quarter worth approximately $48,000. Finally, Plato Investment Management Ltd boosted its stake in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after acquiring an additional 288 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $43.06 on Monday. The stock has a fifty day moving average price of $52.38 and a 200-day moving average price of $90.84. The company has a market cap of $16.57 billion, a price-to-earnings ratio of -7.40 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the firm earned ($1.39) EPS. Moderna’s revenue was up 3.8% on a year-over-year basis. As a group, equities analysts anticipate that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 1,147 shares of company stock valued at $76,245. Corporate insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on MRNA. Jefferies Financial Group reduced their target price on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Piper Sandler reiterated an “overweight” rating and set a $69.00 target price (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Barclays reduced their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research note on Monday, November 18th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $83.33.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.